(MENAFN- Straits Research)
Biologics Market Size, Share & Growth Analysis
The global biologics market size was valued at USD 611.17 billion in 2025 and is projected to grow from USD 672.29 billion in 2026 to USD 1441.11 billion by 2034, registering a CAGR of 10% during the forecast period from 2026 to 2034. North America dominated the biologics market with a market share of 43% in 2025.
Biologics are medical products derived from living organisms or biological sources and are used to prevent, treat, or manage various diseases. They include vaccines, antibodies, cell and gene therapies, and recombinant proteins. The market is driven by the growing prevalence of chronic diseases, advancements in biotechnology, increasing demand for targeted therapies, and rising investment in biopharmaceutical research and development.
Biologics Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 611.17 Billion
2026 Market Size: USD 672.29 Billion
2034 Projected Market Size: USD 1,441.11 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 10%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 43%
Fastest-Growing Region: Europe
Europe CAGR (2026–2034): 8.9%
Segment Insights
By Source
Leading Segment: Mammalian
Market Share in 2025: 71%
By Manufacturing
Fastest-Growing Segment: Outsourced
CAGR: 8.6%
By Product
Leading Segment: Monoclonal Antibodies
Market Share in 2025: 45%
By Disease Category
Fastest-Growing Segment: Oncology
CAGR: 8.8%
By Type
Leading Segment: Tumor Necrosis Factor (TNF) Inhibitor
Market Share in 2025: 28%
By Drug Class
Fastest-Growing Segment: Gene Therapy
CAGR: 11.5%
Download a Free Sample To learn more about this report,
Biologics Market Trends
Growing Development of Advanced Cell and Gene Therapies
The biologics market trends are increasingly driven by innovation in cell therapies, gene therapies, recombinant proteins, vaccines, and other complex biological products. These therapies are expanding treatment options for rare diseases, genetic disorders, cancer, and other serious conditions. The U.S. Food and Drug Administration (FDA) continues to record new biologics approvals through its Center for Biologics Evaluation and Research (CBER), reflecting continued progress in advanced biological medicines.
For instance, in April 2025, the FDA approved ZEVASKYN (prademagene zamikeracel) for the treatment of wounds associated with recessive dystrophic epidermolysis bullosa. The approval demonstrates continued momentum in advanced cell-based therapies and is reinforcing biologics market trends toward more specialized and personalized treatments.
Rising Focus on Expanded Indications and Next-Generation Biologics
The biologics market is also benefiting from the expansion of existing biological products into new patient populations and therapeutic indications. Manufacturers are investing in clinical research to broaden the use of vaccines, immune therapies, and cell-based products, helping address unmet medical needs.
For instance, in May 2025, the FDA approved an additional indication for OMISIRGE (omidubicel-onlv) for adults and pediatric patients aged six years and older with severe aplastic anemia following reduced-intensity conditioning. This expansion highlights the growing focus on extending the clinical applications of advanced biologics and supports continued development of the biologics market.
Biologics Market Dynamics
Market Drivers
Rising Prevalence of Chronic Diseases and Growing Demand for Targeted Therapies
The biologics market growth is primarily driven by the increasing prevalence of chronic and complex diseases, including cancer, autoimmune disorders, inflammatory conditions, diabetes, and rare diseases. Biologics such as monoclonal antibodies, recombinant proteins, vaccines, cell-based therapies, and other biotechnology-derived products are increasingly used because of their ability to target specific biological pathways. The biologics market growth is also supported by advances in biotechnology, genomics, molecular biology, and precision medicine. Growing healthcare expenditure, expanding access to specialty treatments, and increasing investment in biopharmaceutical research are further contributing to market expansion.
Market Restraints
High Development Costs and Complex Manufacturing Processes
The biologics market faces significant restraints due to the high cost and technical complexity associated with biologic drug development and manufacturing. Unlike many conventional small-molecule drugs, biologics often require sophisticated cell culture systems, controlled production environments, specialized purification processes, and extensive quality testing. The biologics market analysis also indicates that long development timelines, stringent regulatory requirements, and high clinical trial costs can create significant barriers to market entry. In addition, cold-chain storage requirements and complex distribution systems can increase overall treatment costs and limit accessibility in regions with limited healthcare infrastructure.
Market Opportunities
Expansion of Biosimilars and Personalized Medicine
The increasing development of biosimilars and personalized treatment approaches is creating significant opportunities for the biologics market. Biosimilars can help expand patient access to biologic therapies by increasing competition and potentially reducing treatment costs. The biologics market analysis highlights growing opportunities in oncology, immunology, rare diseases, regenerative medicine, and targeted therapies. Advances in biomarker identification and genomic testing are also supporting the development of more personalized biologic treatments. Increasing investment in cell and gene therapies, next-generation antibodies, and advanced drug delivery systems is expected to create substantial long-term growth opportunities for market participants.
Market Challenges
Ensuring Manufacturing Consistency and Expanding Patient Access
One of the major challenges facing the biologics market is maintaining consistent product quality across complex biological manufacturing processes. Small variations in cell lines, production conditions, or purification methods can affect product characteristics, requiring rigorous quality control and regulatory oversight. The biologics market growth is also affected by high treatment costs, intellectual property considerations, manufacturing capacity limitations, and shortages of specialized technical expertise. Companies must also manage complex supply chains and cold-storage requirements while expanding access to patients. Balancing scientific innovation, manufacturing reliability, affordability, and regulatory compliance remains a key challenge for companies operating in the global biologics market.
Biologics Market Segmentation
By Source
Mammalian Dominated the Market with 71% Share in 2025
The mammalian segment accounted for the largest share of the global biologics market at 71% in 2025, driven by its widespread use in producing complex biologic therapies, including monoclonal antibodies and recombinant proteins.
The microbial segment continues to play an important role in biologics manufacturing due to its efficient production processes and suitability for developing a range of therapeutic products.
Request Customization to receive a tailored report.
By Manufacturing
In-House Dominated the Market with 66% Share in 2025
The in-house segment accounted for the largest share of the global biologics market at 66% in 2025, supported by greater control over production quality, intellectual property, and manufacturing processes.
Outsourced manufacturing is gaining traction as pharmaceutical and biotechnology companies increasingly rely on specialized contract manufacturers to expand production capacity and reduce operational complexity.
By Product
Monoclonal Antibodies Dominated the Market with 45% Share in 2025
The monoclonal antibodies segment accounted for the largest share of the global biologics market at 45% in 2025, driven by their extensive use in treating cancer, autoimmune diseases, and other chronic conditions.
Vaccines and recombinant proteins remain important product categories, while antisense and RNAi therapeutics are gaining strong attention due to advances in precision medicine and targeted treatment approaches. Other biologic products continue to support the development of innovative therapies.
By Disease Category
Oncology Dominated the Market with 36% Share in 2025
The oncology segment accounted for the largest share of the global biologics market at 36% in 2025, driven by the increasing prevalence of cancer and growing demand for targeted and personalized treatment options.
Infectious diseases and immunological disorders remain major areas for biologic therapies. Cardiovascular and hematological disorders also contribute to market demand, while other disease categories continue to benefit from advances in biologic drug development.
By Type
Tumor Necrosis Factor (TNF) Inhibitor Dominated the Market with 28% Share in 2025
The TNF inhibitor segment accounted for the largest share of the global biologics market at 28% in 2025, supported by its widespread use in treating autoimmune and inflammatory conditions.
T-cell inhibitors, selective co-stimulation modulators, and interleukin blockers continue to support the treatment of immune-related disorders. B-cell inhibitors are also gaining importance as biologic therapies become increasingly targeted and personalized.
By Drug Class
Monoclonal Antibody Dominated the Market with 31% Share in 2025
The monoclonal antibody segment accounted for the largest share of the global biologics market at 31% in 2025, driven by its broad therapeutic applications and increasing adoption in targeted disease treatment.
Vaccines, recombinant insulin, blood factors, and fusion proteins remain important drug classes. Gene therapy and cell therapy are expected to gain strong momentum due to advances in regenerative medicine and precision healthcare, while other biologic drug classes continue to support treatment across diverse medical conditions.
By Source Type
Mammalian Dominated the Market with 67% Share in 2025
The mammalian segment accounted for the largest share of the global biologics market at 67% in 2025, supported by its ability to produce complex therapeutic proteins and advanced biologic medicines.
Microbial sources continue to provide efficient production options for several biologic products, while other sources support specialized manufacturing and emerging therapeutic applications.
By Drug Type
Branded Drugs Dominated the Market with 82% Share in 2025
The branded drugs segment accounted for the largest share of the global biologics market at 82% in 2025, driven by the strong presence of patented biologic therapies and continued investment in innovative drug development.
Generic drugs are gaining traction as healthcare systems seek more affordable treatment options and as patents for existing biologic products expire.
By Mode of Purchase
Prescription Drugs Dominated the Market with 91% Share in 2025
The prescription drugs segment accounted for the largest share of the global biologics market at 91% in 2025, reflecting the need for medical supervision, specialized administration, and careful monitoring associated with most biologic therapies.
Over-the-counter products serve a smaller but important role in selected healthcare applications where biologic-based products can be safely accessed without a prescription.
By Dosage Form
Injection Dominated the Market with 84% Share in 2025
The injection segment accounted for the largest share of the global biologics market at 84% in 2025, driven by the limited oral stability of many biologic medicines and the need for direct delivery into the body.
Tablets and other dosage forms continue to support selected biologic therapies, with ongoing research focused on improving convenient and patient-friendly administration methods.
By Route of Administration
Parenteral Dominated the Market with 86% Share in 2025
The parenteral segment accounted for the largest share of the global biologics market at 86% in 2025, supported by the widespread use of injectable delivery methods for biologic medicines.
Oral and other routes continue to gain attention as pharmaceutical companies develop new formulations aimed at improving convenience and patient compliance.
By End-Users
Hospitals Dominated the Market with 48% Share in 2025
The hospitals segment accounted for the largest share of the global biologics market at 48% in 2025, driven by the availability of specialized infrastructure, trained healthcare professionals, and the high volume of patients requiring advanced biologic treatments.
Specialty clinics play an important role in providing targeted therapies, while homecare is gaining traction as healthcare systems increasingly support convenient treatment administration outside traditional hospital settings.
By Distribution Channel
Hospital Pharmacy Dominated the Market with 52% Share in 2025
The hospital pharmacy segment accounted for the largest share of the global biologics market at 52% in 2025, supported by the close connection between hospitals, healthcare professionals, and the administration of specialized biologic medicines.
Retail pharmacies continue to expand access to selected biologic products, while online pharmacies are gaining momentum due to growing digital healthcare adoption and increasing demand for convenient medicine purchasing and delivery.
Speak to an Analyst to discuss market opportunities.
Biologics Market Regional Outlook
North America Biologics Market Analysis
North America dominated the biologics market with a 43% share, valued at USD 262.80 billion in 2025. The region's leadership is driven by advanced healthcare infrastructure, strong pharmaceutical and biotechnology industries, high healthcare expenditure, and increasing adoption of biologic therapies for chronic and complex diseases. Significant investments in research and development, a strong pipeline of innovative biologics, and growing demand for targeted and personalized treatments continue to support regional market growth.
United States Biologics Market Insights
The United States market accounted for the largest share of the North American market in 2025. Growth is driven by strong investments in biotechnology research, increasing prevalence of chronic diseases, rising adoption of targeted therapies, and expanding demand for advanced treatments in oncology, autoimmune disorders, and other complex conditions. The presence of major pharmaceutical and biotechnology companies and a strong innovation ecosystem further strengthen the country's market position.
Canada Biologics Market Insights
Canada market is witnessing steady market growth due to increasing adoption of advanced biologic therapies, rising healthcare expenditure, growing investments in biotechnology research, and expanding demand for innovative treatments for chronic and complex diseases.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Biologics Market Analysis
Europe market accounted for 29% of the global biologics market, reaching USD 177.24 billion in 2025, and is projected to register a CAGR of 8.9% during the forecast period. Market growth is supported by strong pharmaceutical research capabilities, increasing demand for targeted therapies, rising adoption of biosimilars, and growing investments in biotechnology innovation. Expanding access to advanced treatments and supportive healthcare systems continue to drive regional demand.
United Kingdom Biologics Market Insights
The United Kingdom market is witnessing steady market growth owing to strong biotechnology research capabilities, increasing adoption of biologic and targeted therapies, growing investments in life sciences, and rising demand for advanced treatments for chronic and complex diseases.
Germany Biologics Market Insights
Germany market represents one of the largest markets in Europe, driven by its strong pharmaceutical manufacturing base, advanced healthcare infrastructure, increasing adoption of biologic therapies, growing investments in biotechnology research, and expanding demand for innovative treatments.
Asia Pacific Biologics Market Analysis
Asia Pacific market accounted for 20% of the global biologics market, valued at USD 122.23 billion in 2025. The market is expanding due to increasing healthcare expenditure, growing prevalence of chronic diseases, rising investments in biotechnology and pharmaceutical manufacturing, and improving access to advanced therapies. Large patient populations and growing demand for personalized and targeted treatments continue to support regional market growth.
Japan Biologics Market Insights
Japan market is witnessing steady market growth due to its advanced healthcare system, strong pharmaceutical research capabilities, increasing adoption of innovative biologic therapies, and growing demand for targeted treatments for chronic and complex diseases.
China Biologics Market Insights
China market accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by a large patient population, rising healthcare expenditure, expanding biotechnology manufacturing capacity, increasing investments in drug research and development, and growing adoption of advanced biologic therapies.
Middle East & Africa Biologics Market Analysis
The Middle East & Africa market represented 3% of the global biologics market, totaling USD 18.34 billion in 2025. Rising healthcare investments, increasing prevalence of chronic diseases, expanding access to advanced therapies, and growing government focus on strengthening healthcare infrastructure are supporting regional market growth.
UAE Biologics Market Insights
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare infrastructure, growing adoption of innovative therapies, rising demand for specialized treatments, and expanding government initiatives to strengthen the country's biotechnology and life sciences sectors.
Africa Biologics Market Insights
Africa market is witnessing gradual market growth, supported by increasing healthcare investments, improving access to advanced therapies, rising prevalence of chronic diseases, and growing development of pharmaceutical and biotechnology infrastructure. Countries such as South Africa, Kenya, and Nigeria are creating long-term growth opportunities for market participants.
Competitive Landscape
The global biologics market is highly competitive and innovation-driven, with major pharmaceutical and biotechnology companies competing across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and other advanced biologic therapies. The key players in the industry are Bristol-Myers Squibb Company, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson Services Inc., and F. Hoffmann-La Roche Ltd.. These companies compete through extensive R&D investments, strong biologics pipelines, advanced manufacturing capabilities, regulatory expertise, and global commercialization networks.
The industry participants are focused on expanding biologics portfolios, developing next-generation therapies, strengthening manufacturing capacity, and advancing precision medicine. Strategic collaborations, acquisitions, clinical trials, and the development of biosimilars and novel biologic modalities remain important competitive strategies.
Roche: A Leading Market Player
Roche is a leading player in the biologics market, supported by its strong portfolio of innovative medicines across oncology, immunology, neuroscience, and rare diseases. The company's integrated pharmaceuticals and diagnostics capabilities, combined with significant investments in biologic drug development, strengthen its competitive position globally.
In June 2026, Roche announced that the U.S. FDA granted Priority Review to its supplemental Biologics License Application for Enspryng (satralizumab) for thyroid eye disease, based on results from global Phase III studies.
In July 2026, Roche reported 6% pharmaceutical sales growth at constant exchange rates for the first half of 2026, supported by strong demand for medicines including Hemlibra, Ocrevus, Phesgo, and Vabysmo.
List of Key and Emerging Players in Biologics Market
Bristol-Myers Squibb Company
Merck KGaA
Novartis AG
Novo Nordisk A/S
Pfizer Inc
Johnson & Johnson Services Inc
Hoffmann La Roche Ltd
Key Industry Developments
April 2026: Samsung Biologics expanded its global biologics manufacturing network by commissioning additional large-scale biomanufacturing capacity to support commercial production of monoclonal antibodies and other biologic therapies.
February 2026: Lonza Group launched expanded biologics development and manufacturing services with enhanced mammalian cell culture capabilities for late-stage clinical and commercial production.
October 2025: FUJIFILM Diosynth Biotechnologies expanded its CDMO capabilities through new biomanufacturing facilities dedicated to biologics, cell culture, and recombinant protein production.
June 2025: Thermo Fisher Scientific expanded its biologics manufacturing services by introducing enhanced end-to-end CDMO solutions supporting biologic drug development and commercial manufacturing.
Report Scope
Comments
No comment